- Home
- DBL vs DSGN Comparison
DBL vs DSGN Comparison
Compare DBL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBL
- DSGN
- Stock Information
- Founded
- DBL 2011
- DSGN 2017
- Country
- DBL United States
- DSGN United States
- Employees
- DBL N/A
- DSGN N/A
- Industry
- DBL
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- DBL
- DSGN Health Care
- Exchange
- DBL Nasdaq
- DSGN Nasdaq
- Market Cap
- DBL 280.4M
- DSGN 224.8M
- IPO Year
- DBL N/A
- DSGN 2021
- Fundamental
- Price
- DBL $15.46
- DSGN $3.71
- Analyst Decision
- DBL
- DSGN Hold
- Analyst Count
- DBL 0
- DSGN 1
- Target Price
- DBL N/A
- DSGN $4.00
- AVG Volume (30 Days)
- DBL 61.0K
- DSGN 91.0K
- Earning Date
- DBL 01-01-0001
- DSGN 08-04-2025
- Dividend Yield
- DBL 8.67%
- DSGN N/A
- EPS Growth
- DBL N/A
- DSGN N/A
- EPS
- DBL N/A
- DSGN N/A
- Revenue
- DBL N/A
- DSGN N/A
- Revenue This Year
- DBL N/A
- DSGN N/A
- Revenue Next Year
- DBL N/A
- DSGN N/A
- P/E Ratio
- DBL N/A
- DSGN N/A
- Revenue Growth
- DBL N/A
- DSGN N/A
- 52 Week Low
- DBL $13.75
- DSGN $2.60
- 52 Week High
- DBL $15.70
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- DBL 44.72
- DSGN 47.78
- Support Level
- DBL $15.51
- DSGN $3.66
- Resistance Level
- DBL $15.78
- DSGN $3.84
- Average True Range (ATR)
- DBL 0.13
- DSGN 0.25
- MACD
- DBL -0.01
- DSGN -0.02
- Stochastic Oscillator
- DBL 25.56
- DSGN 18.06
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.